Enanta Pharmaceuticals
Biopharmaceutical company focused on discovery and development of differentiated therapeutics using small-molecule medicinal chemistry and oligonucleotide approaches. The company has a history of developing antiviral combination regimens (including hepatitis C programs) that have reached patient-impacting outcomes, and maintains active pipelines in virology and immunology while operating programs for clinical development, partnerships, and corporate governance.
Industries
Nr. of Employees
medium (51-250)
Enanta Pharmaceuticals
Patents
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US-12552777-B2
View Details
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US-12552777-B2
View DetailsProducts
Antiviral programs — Hepatitis C virus (HCV)
Historic discovery and development contributions to hepatitis C therapeutic regimens that have achieved curative outcomes for patients.
Antiviral programs — Respiratory syncytial virus (RSV)
Development of oral small-molecule inhibitors in a respiratory virus program.
Antiviral programs — Hepatitis B virus (HBV)
Discovery and development activities targeting hepatitis B virus.
Antiviral programs — SARS-CoV-2 / COVID-19
Programs focused on SARS-CoV-2 therapeutic discovery.
Immunology programs — KIT, STAT6 and MRGPRX2 pathways
Discovery efforts targeting immunology pathways, including KIT inhibition, STAT6 inhibition and MRGPRX2 modulation for immune-mediated diseases.
Antiviral programs — Hepatitis C virus (HCV)
Historic discovery and development contributions to hepatitis C therapeutic regimens that have achieved curative outcomes for patients.
Antiviral programs — Respiratory syncytial virus (RSV)
Development of oral small-molecule inhibitors in a respiratory virus program.
Antiviral programs — Hepatitis B virus (HBV)
Discovery and development activities targeting hepatitis B virus.
Antiviral programs — SARS-CoV-2 / COVID-19
Programs focused on SARS-CoV-2 therapeutic discovery.
Immunology programs — KIT, STAT6 and MRGPRX2 pathways
Discovery efforts targeting immunology pathways, including KIT inhibition, STAT6 inhibition and MRGPRX2 modulation for immune-mediated diseases.
Services
Engagement in strategic collaborations, licensing and co-development agreements to advance therapeutic programs.
Engagement in strategic collaborations, licensing and co-development agreements to advance therapeutic programs.
Expertise Areas
- Antiviral drug discovery
- Small-molecule medicinal chemistry
- Oligonucleotide (microRNA) therapeutics
- Clinical trial management
Key Technologies
- Small-molecule inhibitor discovery
- Oligonucleotide / microRNA therapeutics
- Target-based virology (N-protein and other viral targets)
- Preclinical virology assays
News & Updates
Company to present data for an oral once-daily N-protein inhibitor in development for treatment of respiratory syncytial virus.
Company participation in investor conferences in September.
Financial results announcement for the fiscal third quarter ended June 30, 2026.
Discovery and development contributions to combination hepatitis C therapies that have cured more than one million patients.
Company to present data for an oral once-daily N-protein inhibitor in development for treatment of respiratory syncytial virus.
Company participation in investor conferences in September.
Financial results announcement for the fiscal third quarter ended June 30, 2026.
Discovery and development contributions to combination hepatitis C therapies that have cured more than one million patients.